1. Bertocci, B., Gill, G., & Da Prada, M. (1988). Prevention of the DSP-4-induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacogical Research Communications, 20, 131–132.
2. Booze, R. M., Hall, J. A., Cress, N. M., Miller, G. D., & Davis, J. N. (1988). DSP-4 treatment produces abnormal tyrosine hydroxylase immunoreactive fibers in rat hippocampus. Experimental Neurology, 101, 75–86.
3. Bortel, A., Nowak, P., & Brus, R. (2008a). Neonatal DSP-4 treatment modifies GABAergic neurotransmission in the prefrontal cortex of adult rats. Neurotoxicity Research, 13, 247–252.
4. Bortel, A., Slomian, L., Nitka, D., Swierszcz, M., Jaksz, M., Adamus-Sitkiewicz, B., Nowak, P., Josko, J., Kostrzewa, R. M., & Brus, R. (2008b). Neonatal N-(−2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) treatment modifies the vulnerability to phenobarbital- and ethanol-evoked sedative-hypnotic effects in adult rats. Pharmacological Reports: PR, 60, 331–338.
5. Cassano, T., Gaetani, S., Morgese, M. G., Macheda, T., Laconca, L., Dipasquale, P., Taltavull, J., Shippenberg, T. S., Cuomo, V., & Gobbi, G. (2009). Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochemical Research, 34, 1417–1426.